FDA
FDA greenlights Tecentriq for ctDNA-guided treatment in muscle-invasive bladder cancer
Muscle-invasive bladder cancer carries a high risk of recurrence even after cystectomy, yet clinicians have had limited tools to identify which patients are most likely to benefit from adjuvant therapy. FDA has now approved the first circulating tumor DNA (ctDNA)-guided immunotherapy approach in this setting, potentially enabling more personalized treatment decisions after surgery.
On May 15, 2026, FDA approved a new indication for Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) as adjuvant treatment for adults with muscle-invasive bladder cancer who have ctDNA molecular residual disease after cystectomy. The agency simultaneously approved Signatera CDx as the companion diagnostic test for selecting eligible patients.
The approval was based on results from the phase 3 IMvigor011 trial. Among 250 patients with detectable ctDNA molecular residual disease after cystectomy, adjuvant atezolizumab significantly improved disease-free survival compared with placebo. Median disease-free survival was 9.9 months with atezolizumab vs. 4.8 months with placebo (hazard ratio, 0.64; P=.0047).
A statistically significant overall survival benefit was also observed. Median overall survival was 32.8 months with atezolizumab compared with 21.1 months with placebo, corresponding to a 41% relative reduction in risk of death (hazard ratio, 0.59; P=.0131).
IMvigor011 is the first prospective phase 3 trial to demonstrate improved outcomes using a ctDNA-guided approach to adjuvant therapy in muscle-invasive bladder cancer. Patients with negative ctDNA testing may avoid additional therapy and associated toxicity, while ctDNA-positive patients can be identified earlier for intervention before recurrence becomes radiographically apparent.
Tecentriq may be administered intravenously every 2, 3, or 4 weeks for up to one year, while Tecentriq Hybreza is administered subcutaneously every 3 weeks. The prescribing information includes warnings for immune-mediated adverse reactions, infusion-related reactions, complications of allogeneic stem cell transplantation, and embryo-fetal toxicity.
“For the patients and families, the ‘watch and wait’ period after a cystectomy is often defined by uncertainty,” said Meri-Margaret Deoudes, CEO of the Bladder Cancer Advocacy Network. “This ctDNA-guided approach can enable doctors to use serial ctDNA MRD testing to identify who is at a higher risk of recurrence and move quickly toward immunotherapy for those who may benefit from it, while allowing others to safely avoid additional treatment and its associated side effects.”
Sources:
Genentech. (2026, May 15). Press release. FDA approves Genentech’s Tecentriq for adjuvant muscle-invasive bladder cancer with ctDNA-guided treatment
U.S. Food and Drug Administration. (2026, May 15). Press release. FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer in patients with molecular residual disease